AstraZeneca Pharma secures import, market permission for QTERN

26 Sep 2019 Evaluate

AstraZeneca Pharma India has received import and market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10 mg plus Saxagliptin 5mg film coated tablets. The receipt of this Import and Market permission paves way for the launch of FDC of Dapagliflozin 10 mg plus Saxagliptin 5 mg film coated tablets (QTERN) in India.

FDC of Dapagliflozin 10 mg plus Saxagliptin 5 mg is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

6336.90 48.00 (0.76%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.